ESSA Pharma Inc. (EPIX): Price and Financial Metrics


ESSA Pharma Inc. (EPIX): $26.79

-0.43 (-1.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EPIX Stock Price Chart Interactive Chart >

Price chart for EPIX

EPIX Price/Volume Stats

Current price $26.79 52-week high $36.00
Prev. close $27.22 52-week low $4.81
Day low $26.53 Volume 127,100
Day high $27.58 Avg. volume 325,083
50-day MA $29.47 Dividend yield N/A
200-day MA $17.60 Market Cap 904.97M

ESSA Pharma Inc. (EPIX) Company Bio


ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is based in Vancouver, Canada.


EPIX Latest News Stream


Event/Time News Detail
Loading, please wait...

EPIX Latest Social Stream


Loading social stream, please wait...

View Full EPIX Social Stream

Latest EPIX News From Around the Web

Below are the latest news stories about ESSA Pharma Inc that investors may wish to consider to help them evaluate EPIX as an investment opportunity.

ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference

ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr. David R. Parkinson, Chief Executive Officer of ESSA, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference. Dr. Parkinson, along with Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will be available for one-on-one meetings. The conference will take place from June 1 – June 4, 2021.

Yahoo | May 25, 2021

EPIX: Combination Trials Upcoming with Astellas, Bayer, and Janssen…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Phase 1 Trial of EPI-7386 ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen

Yahoo | May 10, 2021

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021

ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

Yahoo | May 6, 2021

ESSA Announces Change to its Board of Directors

HOUSTON, Texas and VANCOUVER, BC, March 26, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Ari Brettman, M.

Yahoo | March 26, 2021

ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing

ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the underwriters have exercised their option (the "Option") to purchase an additional 724,637 common shares in the capital of the Company (the "Common Shares"), in connection with the Company's recently completed underwritten public offering of 4,830,918 Common Shares, which closed on February 22, 2021 (the "Offering"). On closing of the Option, the Company will have issued 5,555,555 Common Shares pursuant to the Offering for gross proceeds of approximately $150 million.

Yahoo | March 4, 2021

Read More 'EPIX' Stories Here

EPIX Price Returns

1-mo -1.33%
3-mo -16.49%
6-mo 278.93%
1-year 430.50%
3-year 554.21%
5-year N/A
YTD 124.56%
2020 116.91%
2019 161.90%
2018 -52.05%
2017 -90.00%
2016 -48.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7552 seconds.